Interesting question and an area where the data is limited but the clinical logic isn't unreasonable.

First, the labeled titration starts at 0.25mg for 4 weeks — but this dose is explicitly described in the prescribing information as a "dose-initiation" dose, not intended to be therapeutic for weight loss. It's meant to acclimate your GI system. The therapeutic dose for weight loss starts at 0.5mg and goes up to 2.4mg.

That said, many patients report meaningful appetite suppression even at 0.25mg, and some providers are prescribing below that for exactly your scenario — smaller patients with less weight to lose.

The pharmacology supports some effect at low doses. GLP-1 receptor binding follows a dose-response curve, and even low receptor occupancy will produce some downstream effects including delayed gastric emptying and central appetite modulation. Whether it produces clinically meaningful weight loss at 0.1mg is genuinely unclear — it wasn't studied in the STEP trials.

My take: it's reasonable to discuss with your provider, especially given your stats. But don't expect the same magnitude of results.

^[1] Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." N Engl J Med. 2021;384(11):989-1002.

I'm 5'0" and started at 0.125mg! My compounding pharmacy actually suggested it because of my size. I did 0.125mg for 6 weeks, then 0.25mg for 4 weeks, then 0.5mg where I've been for 3 months now.

Results at 0.125mg: lost 3 lbs over 6 weeks. Minimal nausea. Definitely noticed reduced appetite but it was subtle — like I just wasn't thinking about food as much. At 0.5mg the appetite suppression is much more obvious but the 0.125mg eased me in beautifully.

Given your stats (similar to mine starting out), I think a gentle start makes a lot of sense. You don't need to slam your system with the standard protocol designed for someone who weighs 250 lbs. 🤷‍♀️

Previously posted:

I think a gentle start makes a lot of sense. You don't need to slam your system with the standard protocol designed for someone who weighs 250 lbs.

I want to push back slightly on this framing. The 0.25mg starting dose in the STEP trials was used across a wide BMI range (27–50+), and the incidence of serious GI adverse events was generally low across all weight categories. The titration schedule was designed to be tolerable for most people, not just larger individuals.

That said, pharmacokinetics do vary by body weight. Semaglutide is distributed in plasma volume which correlates with body weight, so a 140 lb person will have higher mg/kg exposure than a 250 lb person at the same absolute dose. This does provide some pharmacological rationale for lower starting doses in smaller individuals.

I'm not against micro-dosing, I just want to make sure we're being precise about why it might make sense rather than assuming the standard protocol is "too aggressive."

^[1] Lingvay I, et al. "Semaglutide for the Treatment of Obesity." Drugs. 2023;83(2):93-112.

These are all really helpful perspectives. The mg/kg point is exactly what I was trying to articulate — I'm not saying 0.25mg is dangerous for smaller people, just that the relative exposure is higher for me than for someone twice my weight. That seems like a valid reason to consider starting lower.

I think I'll talk to my provider about starting at 0.125mg. If it does nothing after a month, I can always go to 0.25mg. 😊